Drug Trial Radar · NCT07371663
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
266
Planned (sponsor's estimate)
Start
Dec 3, 2025
Primary completion
Sep 30, 2028
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Beijing Tide Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with advanced solid tumors. The Phase II expansion study will assess the efficacy and safety of TCC1727 combined with benmelstobart /olaparib/topotecanin selected advanced solid tumor indications. The study pre-specifies three treatment combinations, with Combination 1 (TCC1727 + benmelstobart) being prioritized for initial evaluation. The decision to proceed with Combination 2 and Combination 3will be based on clinical data from Combination 1.
Conditions
- Solid Cancers
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Gastric (Stomach) Cancer
- Endometrial Cancer
- Malignant Melanoma
Interventions
TCC1727 tablet 90mgDrug
TCC1727 tablets 90 mg, orally, twice daily (bid), continuous dosing in 21-day cycles until disease progression
TCC1727 tablet 120mgDrug
TCC1727 tablets 120 mg, orally, twice daily (bid), continuous dosing in 21-day cycles until disease progression
TCC1727 tablet 160mgDrug
TCC1727 tablets 160 mg, orally, twice daily (bid), continuous dosing in 21-day cycles until disease progression
benmelstobart InjectionCombination product
Administer 1200 mg per dose via intravenous infusion on Day 1 of every 3-week cycle until disease progression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib:To determine dose-limiting toxicity (DLT) at each dose levelTime frame: 21 Days
- MTDTime frame: 21 days
- RP2DTime frame: 21 days
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0Time frame: 21days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.